+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Urinary Tract Infection Market (2023-2028) Competitive Analysis, Impact of Covid-19, Ansoff Analysis

  • PDF Icon

    Report

  • 155 Pages
  • February 2024
  • Region: Global
  • Infogence Global Research
  • ID: 5820319

Urinary tract infections (UTIs) occur far more commonly in women, accounting for at least 8 Mn visits to various types of healthcare facilities in the United States per year

The Global Urinary Tract Infection Market is estimated to be USD 11.46 Bn in 2023 and is expected to reach USD 15.91 Bn by 2028 growing at a CAGR of 6.78%.

Urinary tract infection (UTI) is a common infection that affects any part of the urinary system, including the kidneys, bladder, ureters, and urethra. UTIs are caused by mainly due to bacteria. The most common type of bacteria that causes UTIs is Escherichia coli (E. coli). UTIs can affect people of all ages, but women are more likely to develop them than men due to differences in anatomy.

The market is driven by the Increasing Prevalence of Diabetes and Kidney Stones, High Incidences of UTIs in the Female Population, and Complicated UTIs due to the Rise in Excessive Use of Antibiotics and Drug-Resistance. The high incidence of urinary tract infection (UTI) in the female population is one of the key drivers of the UTI market. Women are more susceptible to UTIs due to their shorter urethra, which allows bacteria to travel more easily to the bladder and cause infection. As per the National Institute of Diabetes and Digestive and Kidney Diseases, women are at a higher risk of UTIs than men, with up to 60% of women experiencing at least one UTI during their lifetime.

However, Adverse Effects of Treatment Drugs such as Aminoglycosides and Azoles are restraining the market growth. Aminoglycosides are a class of antibiotics that can cause damage to the kidneys and the hearing system. Whereas Azoles are another class of antibiotics used to treat UTIs that can cause adverse effects such as liver toxicity, drug interactions, and allergic reactions. In addition, the Social Stigma Concerning Urinary Tract Infections is also a great challenge for the market.

Despite restrain and challenges the rise in R&D for a novel class of antibiotics, vaccines, & devices coupled with the increase in awareness among people and healthcare expenditure is creating great opportunities for the market. This is due to various factors, including the growing prevalence of UTIs, increased access to information through the internet, and increased efforts by healthcare providers and public health campaigns to raise awareness.
  • As more people become aware of UTIs, they are more likely to recognize the symptoms and seek medical attention promptly. Early detection and treatment can help prevent complications and improve outcomes for patients with UTIs. Therefore, the global UTI market is expected to continue to grow in the coming years. Some of the key players in the global UTI market include AbbVie, Inc., Bayer Ag, Cipla, Inc., Merck & Co., Inc., and Pfizer, Inc.

Market Segmentations

  • The Global Urinary Tract Infection Market is segmented based on Clinical Indication, Treatment, End-Users, Seg4, and Geography.
  • By Clinical Indication, the market is classified into Cystitis, Pyelonephritis, and Urethritis. Cystitis holds the largest market share. This is because UTI that affects the bladder and is the most common type of UTI. It is more prevalent in women than men, and it is estimated that up to 50% of women will experience at least one episode of cystitis in their lifetime.
  • By Treatment, the market is classified into Diagnosis and Therapeutics. The Therapeutics segment is expected to hold the largest market share, as it includes the various treatment options available for urinary incontinence, which are in high demand due to the increasing prevalence of the condition.
  • By End-Users, the market is classified into Hospitals & Clinics and Self-Administered. UTIs are mostly performed in hospitals and clinics. The treatment of urinary tract infections (UTIs) in hospitals depends on several factors, including the severity of the infection, the patient's overall health status, and the presence of any underlying medical conditions.
  • By Geography, the market is classified into the Americas, Europe, Middle-East & Africa, and Asia-Pacific. The Americas was the largest regional market for the Global Urinary Tract Infection Market. This is due to the high incidence of UTIs and the availability of advanced healthcare facilities in the region. Other factors such as the increasing prevalence of UTIs and the growing aging population were also expected to contribute to the growth of the UTI market in the Americas.

Recent Developments

1. A new type of antibiotic for treating urinary tract infections (UTIs) may be available sooner than expected. Gepotidacin, manufactured by the pharmaceutical company GSK, is being described as “novel” or “first-in-class”. If approved, gepotidacin would be the first new antibiotic developed for treating UTIs in more than 20 years - Nov 2022
2. Renovia, a digital therapeutics company that specialises in female pelvic floor disorders, has developed a therapeutic device designed to help people strengthen their pelvic floor muscles to treat incontinence - June 2021

Company Profiles

The report provides a detailed analysis of the competitors in the market. It covers the financial performance analysis for the publicly listed companies in the market. The report also offers detailed information on the companies' recent development and competitive scenario. Some of the companies covered in this report are, AbbVie, Inc., Bayer Ag, Cipla, Inc., Merck & Co., Inc., Pfizer, Inc., etc.

Countries Studied

  • America (Argentina, Brazil, Canada, Chile, Colombia, Mexico, Peru, United States, Rest of Americas)
  • Europe (Austria, Belgium, Denmark, Finland, France, Germany, Ireland, Italy, Luxembourg, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, United Kingdom, Rest of Europe)
  • Middle-East and Africa (Egypt, Israel, Nigeria, Qatar, Saudi Arabia, South Africa, United Arab Emirates, Rest of MEA)
  • Asia-Pacific (Australia, Bangladesh, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Sri Lanka, Thailand, Taiwan, Rest of Asia-Pacific)

Competitive Quadrant

The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Ansoff Analysis

  • The report presents a detailed Ansoff matrix analysis for the Global Urinary Tract Infection Market. Ansoff Matrix, also known as Product/Market Expansion Grid, is a strategic tool used to design strategies for the growth of the company. The matrix can be used to evaluate approaches in four strategies viz. Market Development, Market Penetration, Product Development, and Diversification. The matrix is also used for risk analysis to understand the risk involved with each approach.
  • The publisher analyses the Global Urinary Tract Infection Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.
  • Based on the SWOT analysis conducted on the industry and industry players, the publisher has devised suitable strategies for market growth.

Why buy this report?

  • The report offers a comprehensive evaluation of the Global Urinary Tract Infection Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
  • The research report also provides a detailed market size analysis and projections in volume and value terms. The projections are calculated using verified research methodologies.
  • Excel data sheet for the market size will also be provided with the report.
  • The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
  • The report includes an in-depth market analysis using Porter’s 5 forces model, PESTLE Analysis, and the Ansoff Matrix. In addition, the impact of COVID-19 on the market is also featured in the report.
  • The report includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.
  • The report includes Self-Assessment Form, which helps customers evaluate their position in the market compared to their competitors.
  • The report offers customized research - tailored uniquely to our customers with a quick turnaround time. We offer a 15% customization option at no extra charge to all our clients for any of our syndicated reports.

Report Highlights:

  • A complete analysis of the market, including the parent industry
  • Important market dynamics and trends
  • Impact Analysis - a comprehensive assessment to confront risk and make strategic & operational decisions to counter the changes in the market environment.
  • Market segmentation
  • Competitive Analysis: Comparative analysis of competitor
  • Historical, current, and projected size of the market based on value and volume
  • Market size of the US states
  • Market shares and strategies of key players
  • Recommendations to companies for strengthening their foothold in the market

Table of Contents

1 Report Description
1.1 Study Objectives
1.2 Market Definition
1.3 Currency
1.4 Years Considered
1.5 Language
1.6 Key Stakeholders
2 Research Methodology
2.1 Research Process
2.2 Data Collection and Validation
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Models
2.3 Market Size Estimation
2.3.1 Bottom-Up Approach
2.3.2 Top-Down Approach
2.4 Assumptions of the Study
2.5 Limitations of the Study
3 Executive Summary
3.1 Introduction
3.2 Market Size, Segmentations, and Outlook
4 Market Dynamics
4.1 Impact Analysis
4.2 Drivers
4.2.1 Increasing Prevalence of Diabetes and Kidney Stones
4.2.2 High Incidences of UTI in Female Population
4.2.3 Complicated UTI Due to Rise in Excessive Use of Antibiotics and Drug-Resistance
4.3 Restraints
4.3.1 Adverse Effects of Treatment Drugs such as Aminoglycosides and Azoles
4.4 Opportunities
4.4.1 Rise in R&D for a Novel Class of Antibiotics, Vaccines, and Devices
4.4.2 Increase in Awareness among People and Healthcare Expenditure
4.5 Challenges
4.5.1 Social Stigma Concerning Urinary Tract Infections
5 Market Analysis
5.1 Regulatory Scenario
5.2 Porter's Five Forces Analysis
5.3 PESTLE Analysis
5.4 SWOT Analysis
5.5 Impact of COVID-19
5.6 Ansoff Matrix Analysis
6 Global Urinary Tract Infection Market, By Clinical Indication
6.1 Introduction
6.2 Cystitis
6.3 Pyelonephritis
6.4 Urethritis
7 Global Urinary Tract Infection Market, By Treatment
7.1 Introduction
7.2 Diagnosis
7.3 Therapeutics
7.3.1 Aminoglycosides
7.3.2 Azoles
7.3.3 Quinolones
7.3.4 ß-lactam
8 Global Urinary Tract Infection Market, By End-Users
8.1 Introduction
8.2 Hospitals & Clinics
8.3 Self-Administered
9 Americas' Urinary Tract Infection Market
9.1 Introduction
9.2 Argentina
9.3 Brazil
9.4 Canada
9.5 Chile
9.6 Colombia
9.7 Mexico
9.8 Peru
9.9 United States
9.10 Rest of Americas
10 Europe's Urinary Tract Infection Market
10.1 Introduction
10.2 Austria
10.3 Belgium
10.4 Denmark
10.5 Finland
10.6 France
10.7 Germany
10.8 Ireland
10.9 Italy
10.10 Luxembourg
10.11 Netherlands
10.12 Norway
10.13 Poland
10.14 Russia
10.15 Spain
10.16 Sweden
10.17 Switzerland
10.18 United Kingdom
10.19 Rest of Europe
11 Middle East and Africa's Urinary Tract Infection Market
11.1 Introduction
11.2 Egypt
11.3 Israel
11.4 Nigeria
11.5 Qatar
11.6 Saudi Arabia
11.7 South Africa
11.8 United Arab Emirates
11.9 Rest of MEA
12 APAC's Urinary Tract Infection Market
12.1 Introduction
12.2 Australia
12.3 Bangladesh
12.4 China
12.5 India
12.6 Indonesia
12.7 Japan
12.8 Malaysia
12.9 Philippines
12.10 Singapore
12.11 South Korea
12.12 Sri Lanka
12.13 Thailand
12.14 Taiwan
12.15 Rest of Asia-Pacific
13 Competitive Landscape
13.1 Competitive Quadrant
13.2 Market Share Analysis
14 Company Profiles
14.1 AbbVie, Inc.
14.1.1 Company Overview
14.1.2 Company Snapshot
14.1.3 Product Overview
14.1.4 Business Overview
14.1.5 SWOT Analysis
14.1.6 Recent Developments
14.2 Almirall, SA
14.2.1 Company Overview
14.2.2 Company Snapshot
14.2.3 Product Overview
14.2.4 Business Overview
14.2.5 SWOT Analysis
14.2.6 Recent Developments
14.3 AstraZeneca PLC
14.3.1 Company Overview
14.3.2 Company Snapshot
14.3.3 Product Overview
14.3.4 Business Overview
14.3.5 SWOT Analysis
14.3.6 Recent Developments
14.4 Bayer Ag
14.4.1 Company Overview
14.4.2 Company Snapshot
14.4.3 Product Overview
14.4.4 Business Overview
14.4.5 SWOT Analysis
14.4.6 Recent Developments
14.5 Boehringer Ingelheim International GmbH
14.5.1 Company Overview
14.5.2 Company Snapshot
14.5.3 Product Overview
14.5.4 Business Overview
14.5.5 SWOT Analysis
14.5.6 Recent Developments
14.6 Bristol-Myers Squibb Co.
14.6.1 Company Overview
14.6.2 Company Snapshot
14.6.3 Product Overview
14.6.4 Business Overview
14.6.5 SWOT Analysis
14.6.6 Recent Developments
14.7 Cipla, Inc.
14.7.1 Company Overview
14.7.2 Company Snapshot
14.7.3 Product Overview
14.7.4 Business Overview
14.7.5 SWOT Analysis
14.7.6 Recent Developments
14.8 Dr. Reddys Laboratories Ltd.
14.8.1 Company Overview
14.8.2 Company Snapshot
14.8.3 Product Overview
14.8.4 Business Overview
14.8.5 SWOT Analysis
14.8.6 Recent Developments
14.9 Eli Lilly and Co.
14.9.1 Company Overview
14.9.2 Company Snapshot
14.9.3 Product Overview
14.9.4 Business Overview
14.9.5 SWOT Analysis
14.9.6 Recent Developments
14.10 F. Hoffmann-La Roche Ag
14.10.1 Company Overview
14.10.2 Company Snapshot
14.10.3 Product Overview
14.10.4 Business Overview
14.10.5 SWOT Analysis
14.10.6 Recent Developments
14.11 GSK PLC
14.11.1 Company Overview
14.11.2 Company Snapshot
14.11.3 Product Overview
14.11.4 Business Overview
14.11.5 SWOT Analysis
14.11.6 Recent Developments
14.12 Johnson & Johnson
14.12.1 Company Overview
14.12.2 Company Snapshot
14.12.3 Product Overview
14.12.4 Business Overview
14.12.5 SWOT Analysis
14.12.6 Recent Developments
14.13 Merck & Co., Inc.
14.13.1 Company Overview
14.13.2 Company Snapshot
14.13.3 Product Overview
14.13.4 Business Overview
14.13.5 SWOT Analysis
14.13.6 Recent Developments
14.14 Mindray Medical International Ltd.
14.14.1 Company Overview
14.14.2 Company Snapshot
14.14.3 Product Overview
14.14.4 Business Overview
14.14.5 SWOT Analysis
14.14.6 Recent Developments
14.15 Novartis Ag
14.15.1 Company Overview
14.15.2 Company Snapshot
14.15.3 Product Overview
14.15.4 Business Overview
14.15.5 SWOT Analysis
14.15.6 Recent Developments
14.16 Novo Nordisk AS
14.16.1 Company Overview
14.16.2 Company Snapshot
14.16.3 Product Overview
14.16.4 Business Overview
14.16.5 SWOT Analysis
14.16.6 Recent Developments
14.17 Pfizer, Inc.
14.17.1 Company Overview
14.17.2 Company Snapshot
14.17.3 Product Overview
14.17.4 Business Overview
14.17.5 SWOT Analysis
14.17.6 Recent Developments
14.18 Shionogi & Co., Ltd.
14.18.1 Company Overview
14.18.2 Company Snapshot
14.18.3 Product Overview
14.18.4 Business Overview
14.18.5 SWOT Analysis
14.18.6 Recent Developments
14.19 Siemens Healthcare Ag
14.19.1 Company Overview
14.19.2 Company Snapshot
14.19.3 Product Overview
14.19.4 Business Overview
14.19.5 SWOT Analysis
14.19.6 Recent Developments
14.20 Sun Pharmaceutical Industries Ltd.
14.20.1 Company Overview
14.20.2 Company Snapshot
14.20.3 Product Overview
14.20.4 Business Overview
14.20.5 SWOT Analysis
14.20.6 Recent Developments
14.21 Sysmex Corp.
14.21.1 Company Overview
14.21.2 Company Snapshot
14.21.3 Product Overview
14.21.4 Business Overview
14.21.5 SWOT Analysis
14.21.6 Recent Developments
14.22 Teva Pharmaceutical Industries Ltd.
14.22.1 Company Overview
14.22.2 Company Snapshot
14.22.3 Product Overview
14.22.4 Business Overview
14.22.5 SWOT Analysis
14.22.6 Recent Developments
14.23 Urit Medical Electronic Co., Ltd.
14.23.1 Company Overview
14.23.2 Company Snapshot
14.23.3 Product Overview
14.23.4 Business Overview
14.23.5 SWOT Analysis
14.23.6 Recent Developments
14.24 Viatris, Inc.
14.24.1 Company Overview
14.24.2 Company Snapshot
14.24.3 Product Overview
14.24.4 Business Overview
14.24.5 SWOT Analysis
14.24.6 Recent Developments
15 Appendix
15.1 Self-Assessment Form

Companies Mentioned

  • AbbVie, Inc.
  • Almirall, SA
  • AstraZeneca PLC
  • Bayer Ag
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Co.
  • Cipla, Inc.
  • Dr. Reddys Laboratories Ltd.
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ag
  • GSK PLC
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Mindray Medical International Ltd.
  • Novartis Ag
  • Novo Nordisk AS
  • Pfizer, Inc.
  • Shionogi & Co., Ltd.
  • Siemens Healthcare Ag
  • Sun Pharmaceutical Industries Ltd.
  • Sysmex Corp.
  • Teva Pharmaceutical Industries Ltd.
  • Urit Medical Electronic Co., Ltd.
  • Viatris, Inc.

Table Information